top of page
Search

Lipoprotein (a) Deep Dive

A new study shows that getting your LDL very low helps but still may not quite be enough to fully eliminate risk. Let's use it's findings to help discuss this topic in detail.


This study was just published in the European Heart Journal and followed over 1,500 Japanese heart disease patients for about 5 years after stent placement. Researchers were among a specific question: if we get LDL cholesterol down to aggressive guideline targets, does that cancel out the danger of high Lp(a)?


The answer: not completely.


Even patients who hit the aggressive LDL goal of under 55 mg/dL still had higher rates of heart attacks, cardiac death, and repeat procedures if their Lp(a) was elevated. These were the numbers:


• Lp(a) under 30: 5% 5-year event rate


• Lp(a) 30–50: 17% 5-year event rate


• Lp(a) over 50: 33% 5-year event rate


To put that in plain terms: out of every 100 people with high Lp(a) and very well-controlled LDL, 5, 17, or 33 still had a major cardiac event within 5 years depending on their Lp(a) levels.


That’s nearly 7x the risk, between low and high Lp(a).


HOWEVER, PLEASE ALSO NOTE: lowering LDL did meaningfully help. Patients with high Lp(a) who didn’t hit the LDL target had even worse outcomes, so aggressive LDL lowering is still doing important work. It just isn’t the whole answer when Lp(a) is elevated.


So what else can someone do about their high Lp(a)?


Occasional anecdotes aside, we can’t reliably change the Lp(a) number much with diet or lifestyle because it’s mostly genetic. And eating a low carb diet like some recommend may help lower Lp(a) but simultaneously raise risk from various other angles.


However, it’s VERY IMPORTANT TO NOTE the damage Lp(a) causes can still be heavily influenced by what’s happening in the rest of your body. So think of Lp(a) as causing sparks, but inflammation and metabolic dysfunction are like gasoline.


Here are things you can do aside from aggressively lowering LDL/apoB that can further lower risk even though they don’t lower Lp(a):


• Reduce inflammation: Studies show that elevated CRP (a marker of systemic inflammation) compounds Lp(a) risk significantly. Patients with both high Lp(a) and high CRP have dramatically worse outcomes than those with high Lp(a) alone. A plant-rich anti-inflammatory diet, quality sleep, and stress reduction all move CRP in the right direction.


• Waist-to-hip ratio matters more than you might think: Research has found that central adiposity (belly fat specifically) interacts with Lp(a) to amplify cardiovascular risk. A higher waist-to-hip ratio worsens the Lp(a) risk profile, meaning carrying excess weight around the middle isn’t just independently bad, it appears to make high Lp(a) more dangerous. This is a modifiable target.


• High-dose EPA (specifically): The REDUCE-IT trial showed meaningful reduction in heart events in high cardiovascular risk patients using high-dose EPA (icosapentaenoic acid), independent of LDL lowering. For someone with high Lp(a), reducing residual inflammatory and triglyceride-driven risk matters.


• Control blood sugar: Insulin resistance and elevated glucose accelerate the vascular inflammation and oxidative stress through which Lp(a) causes harm.


• Blood pressure: Hypertension and high Lp(a) are a particularly dangerous combination. Elevated blood pressure accelerates endothelial damage, and Lp(a) exploits that damaged endothelium to drive plaque formation. Getting blood pressure consistently below 130/80 (ideally lower) is one of the most impactful things a high-Lp(a) patient can do.


• Sleep apnea: Untreated obstructive sleep apnea causes repeated nighttime oxygen drops, spikes in sympathetic nervous system activity, and chronic inflammation, all of which amplify cardiovascular risk independently. In the context of high Lp(a), this is a meaningful accelerator that often goes undiagnosed. If you snore, wake unrefreshed, or have been told you stop breathing at night, get tested.


• Oral health: Periodontal disease is a genuine and under-appreciated cardiovascular risk accelerator. Chronic low-grade infection and inflammation from gum disease feeds the same inflammatory milieu that makes Lp(a) more dangerous.


• Skip the niacin: While niacin can modestly lower Lp(a), the AIM-HIGH and HPS2-THRIVE trials showed no reduction in cardiovascular events when niacin was added and HPS2-THRIVE found a significant increase in serious adverse effects including liver toxicity, GI bleeding, and infections.


What about supplements commonly touted for Lp(a)?


This comes up a lot. Here's a look at what the evidence actually shows:


• Vitamin C: Some interest here based on Linus Pauling’s older work suggesting high-dose vitamin C may modestly lower Lp(a). Small studies have shown some signal, but the evidence is weak, inconsistent, and there are no meaningful outcomes data. It’s not harmful at moderate doses, but don’t count on it as your primary intervention.


• Lysine and proline: Often bundled with vitamin C in the “Pauling protocol". The theoretical basis is interesting but clinical evidence is essentially absent. Again, not harmful, but just take a balanced perspective on them.


• Coenzyme Q10 / ubiquinol: Frequently recommended in Lp(a) circles. No good evidence it significantly lowers Lp(a) or reduces Lp(a)-associated risk specifically. It may have some general benefits for mitochondrial health and statin-related muscle symptoms.


• Tocotrienols (part of the vitamin E family): Some small studies suggest modest Lp(a) lowering. Evidence quality is low so far. Possibly helpful but not a singular reliable strategy.


Bottom line on supplements: the honest answer is that nothing in this category has been shown in rigorous trials to meaningfully lower Lp(a) or reduce the cardiovascular risk it causes. Most are harmless, but none should be considered as a substitute for the other strategies above.


More Meds?


The most important pharmacological move right now: get LDL/apoB as low as possible via meds you tolerate (adding good diet and exercise works synergistically here). Since we don’t yet have an approved Lp(a)-lowering drug, the best strategy is to reduce the overall “atherogenic load” by driving LDL and apoB down aggressively. PCSK9 inhibitors (drugs like Repatha or Praluent) are the strongest tool for this, though combining low to moderate dose statin plus ezetimibe/zetia can also work very well especially when diet and exercise are solid.


Additional point about PCSK9 inhibitors: post-hoc analyses from major trials (FOURIER and ODYSSEY OUTCOMES) found that patients with the highest Lp(a) got the greatest benefit specifically from PCSK9 inhibitors. These drugs are not only most potent at lowering LDL/apoB, they also modestly lower Lp(a) itself by around 20–30%, on top of cutting LDL dramatically. So for someone with high Lp(a), a PCSK9 inhibitor may offer more than just LDL lowering.


The future looks genuinely hopeful:


Several drugs that directly target Lp(a), reducing it by 70–90%+, are in large outcomes trials right now. We should have more real answers within the next few years on whether actually directly lowering Lp(a) prevents heart attacks.


And also keep an eye on a forthcoming drug called obicetrapib, a once-daily pill currently in trials that appears impressively safe, and lowers LDL by ~45% and Lp(a) by ~33%, while simultaneously improving HDL functionality. For people who need additional lipid lowering beyond statins and other agents, this could become an important option.


Please check your Lp(a) if you haven’t. It’s elevated in about 20% of the general population, and more in certain ethnicities. If it’s elevated, even with “good” cholesterol numbers, your risk picture looks different and your treatment plan should reflect that and be as thorough as possible.



 
 
bottom of page